Skip to content

The Effect of Remote Ischemic Postconditioning on Liver Graft and Renal Function in Patients Undergoing Living-related Liver Transplantation

The Effect of Remote Ischemic Postconditioning on Liver Graft and Renal Function in Patients Undergoing Living-related Liver Transplantation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01637038
Enrollment
80
Registered
2012-07-10
Start date
2012-06-30
Completion date
2013-02-28
Last updated
2013-12-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemia/Reperfusion Injury of Kidney, Ischemia/Reperfusion Injury of Liver Graft, Remote Ischemic Postconditioning

Keywords

ischemia/reperfusion injury, remote ischemic postconditioning

Brief summary

The investigators are trying to evaluate the clinical effect of remote ischemic postconditioning on liver graft function and postoperative renal function in subjects undergoing living-donor liver transplantation.

Detailed description

Ischemic reperfusion injury of liver graft and postoperative renal dysfunction is a common problem which influence poor outcome in subjects undergoing liver transplantation. The incidence of postoperative renal dysfunction was reported as high as 12 \ 64% and is thought to be caused by ischemia/reperfusion injury. Ischemic pre- or postconditioning was reported to be effective for preventing ischemia/reperfusion injury during liver transplantation. Remote ischemic pre- or postconditioning was also reported to be protective for ischemia/reperfusion injury in major organs in previous animal studies. Therefore, we are trying to evaluate the clinical effect of remote ischemic postconditioning on liver graft function and postoperative renal function in subjects undergoing living-donor liver transplantation.

Interventions

OTHERRIPC

Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Subjects undergoing living donor liver transplantation during the study period * Subjects older than 20 yrs who can give written informed consent

Exclusion criteria

* Re-transplanted recipients * Those with peripheral vascular diseases affecting the extremities * Those with hepatic encephalopathy * Those with cirrhotic cardiomyopathy

Design outcomes

Primary

MeasureTime frameDescription
total bilirubinbefore surgery and at 6, 12, 24, 36, 48, 60, 72, 84, 96 hours after the end of surgerytotal bilirubin before surgery and at 6, 12, 24, 36, 48, 60, 72, 84, 96 hours after the end of surgery

Secondary

MeasureTime frameDescription
Renal Function Test profilesBefore surgery and at 6, 12, 24, 36, 48, 60, 72, 84, 96 hours after the end of surgerySerum BUN, creatinine concentration, estimated GFR and urine output before surgery and at 6, 12, 24, 36, 48, 60, 72, 84, 96 hours after the end of surgery
Liver Function Test Profilesbefore surgery and at 6, 12, 24, 36, 48, 60, 72, 84, 96 hours after the end of surgeryAST, ALT, albumin, before surgery and at 6, 12, 24, 36, 48, 60, 72, 84, 96 hours after the end of surgery
incidence of Surgical Outcome1 week, 1 month after the end of surgeryincidence of acute rejection of transplanted Liver (Biopsy-confirmed or clinically symptomatic),incidence of Delayed graft function : clinically symptomatic, incidecne of Postoperative renal replacement therapy
Length of hospital stay (days)1 month, 2 month, 3 month after the end of surgerytotal hospital stay, ICU stay, postoperative stay

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026